Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria

Diagnostic Microbiology and Infectious Disease

Volumn 37, Issue 4, 2000, Pages 265-269

  Fuchs, Peter C ^a   Barry, Arthur L ^a   Brown, Steven D ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFACLOR; CEFDITOREN; CEFOTAXIME; OFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; DATA ANALYSIS; DIFFUSION; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SPECIES DIFFERENCE; STREPTOCOCCUS PNEUMONIA;

AMPICILLIN; ANTI-INFECTIVE AGENTS; CEFACLOR; CEFOTAXIME; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; HAEMOPHILUS INFLUENZAE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PENICILLINS; STREPTOCOCCUS PNEUMONIAE;

EID: 0034253888     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(00)00160-7     Document Type: Article

References (14)

1. Doern, G. V., Brueggemann, A. B., Pierce, G., Holley H. P. Sr., & Rauck, A. (1997). Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. Antimicrob Agents Chemother, 41, 292-297.
2. Felmingham D., Robbins M.J., Ghosh G., Bhogal H., Mehta M.D., Leakey A., Clark S., Dencer C.A., Ridgway G.L., Gruneberg R.N. An in vitro characterization of cefditoren, a new oral cephalosporin. Drugs Exp Clin Res. 20:1994;127-147.
3. Iwai N., Nakamura H., Miyazu M., Watanabe Y. Pharmacokinetic, bacteriological and clinical evaluation of cefditoren pivoxil in pediatrics. Jpn J Antibiot. 47:1994;181-194.
4. Jones, R. N., Biedenbach, D. J., Croco, M. A. T., & Barrett, M. S. (1998). In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae. Moraxella Catarrhalis, and Streptococcus Pneumoniae Diagn Microbiol Infect Dis, 31, 573-578.
5. Li J.T., Hou F., Lu H., Li T.Y., Li H. Phase I clinical trial of cefditoren pivoxil (ME 1207) pharmacokinetics in healthy volunteers . Drugs Exp Clin Res. 23:1997;145-150.
6. National Committee for Clinical Laboratory Standards (NCCLS). (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved standard M7-A4. Wayne, PA: NCCLS.
7. National Committee for Clinical Laboratory Standards (NCCLS). (1997). Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard M2-A6. Wayne, PA: NCCLS.
8. National Committee for Clinical Laboratory Standards (NCCLS). (1999). Performance Standards for Antimicrobial Susceptibility Tests. Ninth Informational Supplement M100-S9. Wayne, PA: NCCLS.
9. Soriano F., Coronel P., Gimeno M., Jimenez M., Garcia-Corbeira P., Fernandez-Roblas R. Inoculum effect and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis. Eur J Clin Microbiol Infect Dis. 15:1996;761-763.
10. Spangler S.K., Jacobs M.R., Appelbaum P.C. Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other β-lactams. J Antimicrob Chemother. 39:1997;141-148.
11. Spangler S.K., Jacobs M.R., Appelbaum P.C. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 40:1996;481-484.
12. Sugita R., Deguchi K., Fujimaki Y., Harada S., Shimizu K., Kimura S., Watanabe H., Komatsu N., Okano K., Naito M., Nomura T., Tanaka M., Yoshida Y., Tanaka H., Iwai N., Nakamura H. Clinical efficacy in pediatric sinusitis infections of cefditoren pivoxil granule therapy and its in vitro antibacterial activity against clinically isolated strains. Jpn J Antibiot. 50:1997;727-737.
13. Sugita R., Deguchi K., Kimura S., Harada S., Fujimaki Y., Watanabe H., Naito M., Nomura T., Tanaka M., Komatsu N., Yoshida Y., Okano K. Efficacy of cefditoren pivoxil in the treatment of acute otitis media due to benzylpenicillin-insensitive Streptococcus pneumoniae. Jpn J Antibiot. 49:1996;386-398.
14. Toyonaga Y., Ishihara T., Sano T., Tezuka T., Nakamura H. Bacteriological, pharmacokinetic and clinical studies of cefditoren pivoxil in the pediatric field. Jpn J Antibiot. 46:1993;604-628.